Company that hiked drug price 5,000% investigated by U.S. Senate



Estimated read time: 1-2 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (CNNMoney) — The U.S. Senate has launched an investigation into Turing Pharmaceuticals — the drug company that hiked the price of a life-saving drug by 5,000 percent.

In a letter released Wednesday, the Senate Special Committee on Aging said it was looking into the "pricing of off-patent drugs," and requested information from Turing CEO Martin Shkreli.

The committee will investigate Turing's "acquisition of the rights to sell Daraprim," and the decision to raise the price from $13.50 a pill to $750.00.

Daraprim is a drug used by some AIDS and cancer patients to treat a life-threatening, parasitic infection called toxoplasmosis.

Although Daraprim has been around for decades, Shkreli's Turing Pharmaceuticals only acquired the rights to sell the drug in August. Soon after, Turing hiked the price.

Related:

Despite publicly saying he would lower the cost, the drug remains prohibitively expensive.

Shkreli has been ordered to provide a variety of documentation and information about Turing's business to the committee by December 2, 2015.

Among the committee's requests, it asked for the identity of "the Turing employee responsible for setting the price of Daraprim."

The drug pricing controversy even sparked reaction from Democratic presidential candidates.

Hillary Clinton called for an investigation into Turing and criticized drug companies for price gouging.

Bernie Sanders rejected a $2,700 campaign donation from Shkreli. Shkreli didn't take the rejection well — he said he was so angry at Sanders he "could punch a wall!"

The-CNN-Wire™ & © 2015 Cable News Network, Inc., a Time Warner Company. All rights reserved.

Related Stories

Ahiza Garcia

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast